MedPath

Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Clinical Trials
Related News

FDA Approves Spravato (Esketamine) Nasal Spray as Standalone Treatment for Treatment-Resistant Depression

• The FDA has approved Spravato (esketamine) nasal spray as a monotherapy for adults with treatment-resistant depression (TRD). • Spravato demonstrated rapid and superior improvement in depressive symptoms compared to placebo in clinical trials. • The approval was based on a study where 22.5% of patients achieved remission with Spravato compared to 7.6% with placebo. • Due to risks, Spravato is only available through a restricted program under the supervision of a healthcare provider.

Psilocybin Shows Promise as Alternative Depression Treatment, Outperforming SSRIs in Some Measures

• A recent study compared psilocybin to escitalopram (Lexapro), a common SSRI, for treating depression, revealing psilocybin's potential as an alternative treatment. • Psilocybin demonstrated comparable improvement in depressive symptoms to escitalopram, with patients reporting greater joy and well-being. • Psilocybin works by desynchronizing the brain's ruminative area, disrupting negative thought patterns and allowing for new perspectives. • Experts caution about the need for further research on psilocybin's long-term effects, scalability, and potential risks in diverse populations.

Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion, Bolstering Epilepsy Pipeline

• Lundbeck will acquire Longboard Pharmaceuticals for $2.6 billion, gaining bexicaserin, a promising drug for developmental and epileptic encephalopathies (DEEs). • Bexicaserin, a 5-HT2C receptor superagonist, has shown encouraging results in clinical trials for reducing seizure frequency in Dravet syndrome and other DEEs. • The acquisition aligns with Lundbeck's strategy to expand its neuro-rare disease portfolio, with bexicaserin potentially launching in 2028 and reaching peak sales of $1.5-2 billion. • The deal is expected to close in the fourth quarter of 2024, pending regulatory approvals and tender of Longboard's outstanding shares.

Antidepressant Escitalopram Shows Potential to Enhance Memory and Cognitive Function

• A new study indicates that the antidepressant escitalopram (Lexapro) may improve memory and cognitive skills in patients. • The research links escitalopram's cognitive benefits to increased activity in the brain's 5HT4 serotonin receptor. • Cognitive tests showed improved recall ability in patients treated with escitalopram for eight weeks, correlating with enhanced 5HT4 receptor function. • Future research will explore drugs specifically targeting the 5HT4 receptor to treat cognitive impairments, regardless of depression symptoms.

Psilocybin Shows Promise as Alternative to SSRIs for Depression Treatment

• A recent study indicates that psilocybin, the active compound in magic mushrooms, offers comparable long-term benefits to escitalopram for treating depression. • Psilocybin outperformed escitalopram in enhancing psychosocial functioning, including a greater sense of meaning in life and improved social connectedness. • Researchers emphasize that psilocybin is still experimental and should only be administered in controlled environments due to potential risks. • Experts caution that not everyone is a candidate for psilocybin treatment, particularly those with a history of psychosis or bipolar disorder.

Psychedelics Show Promise in Treating Anxiety and Depression in Advanced Cancer Patients

• Psychedelic drugs, including psilocybin, LSD, and MDMA, may significantly alleviate depression and anxiety in advanced cancer patients, where conventional antidepressants often fall short. • A meta-analysis revealed that psychedelics reduced depression scores by six points and anxiety scores by seven to eight points, demonstrating a clinically meaningful improvement. • In a trial with cancer patients, 60% receiving psilocybin achieved depression remission, and 52% achieved anxiety remission, compared to 16% and 12% respectively with a placebo. • Psychedelic therapy may address underlying trauma associated with cancer diagnosis and treatment, offering a potential advantage over traditional antidepressants.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy